Bodyport is a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions by embedding a sophisticated biomarker platform into simple, easy-to-use devices. The Bodyport for Heart Health solution captures hemodynamic signals through the Bodyport Cardiac Scale to power optimized interventions for patients.By not requiring a wearable device or surgical implant, the solution seamlessly integrates into a patient’s daily life.
Bodyport is focused on keeping patients with cardiorenal conditions healthier & out of the hospital and is tackling heart failure first to noninvasively assess heart function & fluid status in a single step at home.
Bodyport is backed by Boehringer Ingelheim Venture Fund, Playground Global, Initialized Capital, Y Combinator & Rock Health.
ACC.22 Learning Pathways? (select all that apply) Heart Failure and Cardiomyopathies